Literature DB >> 2781718

Factors affecting the efficacy of ivermectin against Heligmosomoides polygyrus (Nematospiroides dubius) in mice.

F N Wahid1, J M Behnke, D J Conway.   

Abstract

The efficacy of ivermectin against Heligmosomoides polygyrus was investigated in 5 mouse strains (CFLP, NIH, C57Bl10, BALB/c and CBA) using a variety of dose levels, and subcutaneous and oral administration. Heligmosomoides polygyrus were not completely eliminated when 5 mg kg-1 of ivermectin was given 6 days after infection, but 10 mg kg-1 was totally effective. Significant mouse-strain variation in drug efficacy was detected, NIH mice requiring treatment with higher doses than CFLP mice in order to bring about a comparable level of larvicidal activity. Ivermectin was more effective when given subcutaneously than when given orally, regardless of the dose administered or the strain of mouse tested. The anthelmintic effect of the treatment was more persistent in CFLP mice given 20 mg kg-1 subcutaneously than in NIH mice or in mice treated orally, and a 20-day interval between administration and infection was insufficient to prevent inhibition of parasite survival. Ivermectin was shown to be totally effective at 20 mg kg-1 given subcutaneously in killing immune arrested larvae of H. polygyrus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2781718     DOI: 10.1016/0304-4017(89)90043-5

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  2 in total

1.  Bacillus thuringiensis Cry5B protein is highly efficacious as a single-dose therapy against an intestinal roundworm infection in mice.

Authors:  Yan Hu; Sophia B Georghiou; Alan J Kelleher; Raffi V Aroian
Journal:  PLoS Negl Trop Dis       Date:  2010-03-02

2.  Variation in Local and Systemic Pro-Inflammatory Immune Markers of Wild Wood Mice after Anthelmintic Treatment.

Authors:  Evelyn C Rynkiewicz; Melanie Clerc; Simon A Babayan; Amy B Pedersen
Journal:  Integr Comp Biol       Date:  2019-11-01       Impact factor: 3.326

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.